Cluster Headache Has New Trial Data. Ketamine Clinics Should Be Paying Attention
Clinicians call it the suicide headache. Between 47 and 55 percent of people with cluster headache report suicidal thoughts. They are also about 5.6 times more likely to be depressed. Two randomized trials published in 2024 now suggest psilocybin can reduce how often the attacks come. That combination should interest anyone running an interventional psychiatry practice.
Serving a new patient population costs less when your supply and insurance lines are already optimized. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The condition | Attacks last 15 to 180 minutes and can strike up to eight times a day |
| The psychiatric load | Between 47 and 55 percent of patients report suicidal thoughts. Depression is roughly 5.6 times more likely |
| The new evidence | Two 2024 randomized trials of pulse dose psilocybin cut attack frequency by roughly 50 percent and 31 percent |
| Where ketamine sits | It appears among abortive options with strong preliminary evidence and no controlled trials yet |
| The access gap | Only Oregon, Colorado and New Mexico offer legal supervised psilocybin, so most patients cannot reach it |
What the Condition Does
Cluster headache produces attacks around one eye. Each lasts 15 to 180 minutes. They can arrive up to eight times in a single day.
Episodic patients get attack periods lasting weeks or months. Chronic patients go a full year without a meaningful break. Roughly 10 to 20 percent of chronic cases resist available treatment entirely.
That refractory group is small in percentage terms and desperate in practice. They have usually tried everything on the standard list.
What the Standard List Looks Like
Abortive care leans on high flow oxygen and triptans such as sumatriptan. Ergotamine derivatives exist but see little use because of side effects.
Prevention runs through verapamil, lithium, topiramate and CGRP antagonists like galcanezumab. Ketamine also appears on the abortive side. The evidence there is described as strong but preliminary, and controlled trials have not yet been done.
Read that carefully. Ketamine sits in the clinical conversation for this condition already, without the trial base to settle the question.
The New Controlled Data
Psilocybin and LSD have been studied for headache for more than 60 years. Both act on the same serotonin receptor. What changed in 2024 was the arrival of randomized evidence.
A US trial gave 10 patients three doses of psilocybin five days apart, with another pulse six months later. Attack frequency fell by roughly 50 percent. Chronic patients held that reduction across eight weeks.
A Danish trial used a similar pulse schedule at a lower dose. Frequency dropped about 31 percent. One participant reached 21 weeks of complete remission.
Both trials are very small. A Swiss case series of nine patients found six stopped having attacks after psilocybin or LSD. Two larger LSD trials are now underway.
Why Doses Stayed Low
One detail matters for how this might eventually work in practice. The benefit in this research comes from therapeutic microdoses rather than full psychedelic sessions.
Patients in these protocols were not having six hour experiences. That changes the staffing and monitoring picture considerably compared with psilocybin protocols for depression.
These Patients May Already Be Yours
Return to the psychiatric numbers. Half of this population reports suicidal ideation. Depression risk runs several times higher than normal.
Those patients are already seeking treatment resistant depression care. Some are sitting in ketamine chairs right now with their headache history buried somewhere in intake, treated as a separate problem by a separate specialist.
Asking about it costs one screening question. We covered the patient side of this story in our earlier look at psychedelics and suicide headaches, and the broader pain evidence in our guide to ketamine for chronic pain.
The Access Problem Is the Real Constraint
Here is what limits all of this. Only Oregon, Colorado and New Mexico provide legal supervised psilocybin access. Everywhere else, the compound that produced the 2024 results is unavailable to patients through legitimate channels.
Some patients solve that themselves, which is part of why naturalistic use keeps showing up in headache research. That is not a treatment pathway a clinic can recommend.
What to Do With This
Three things are reasonable now.
Screen for it. Add a headache question to intake. The overlap with your existing depression population is real.
Know the evidence honestly. Ketamine has preliminary support for cluster headache and no controlled trials. Say exactly that to patients who ask, and nothing more.
Watch the LSD trials. Two are running with larger samples. If they replicate the 2024 psilocybin results, the pressure for supervised access will build quickly, and clinics with monitoring capacity will be the ones positioned to answer it.
